Lunit Inc. (KOSDAQ:328130)

South Korea flag South Korea · Delayed Price · Currency is KRW
36,400
-2,500 (-6.43%)
Mar 20, 2026, 3:30 PM KST
Market Cap1.07T -41.6%
Revenue (ttm)83.13B +53.4%
Net Income-46.63B
EPS-1,596.60
Shares Out29.28M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume367,046
Average Volume214,751
Open38,900
Previous Close38,900
Day's Range36,400 - 40,400
52-Week Range32,750 - 60,700
Beta1.16
RSI43.22
Earnings DateMay 14, 2026

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Sector Technology
Founded 2013
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 328130
Full Company Profile

Financial Performance

In 2025, Lunit's revenue was 83.13 billion, an increase of 53.43% compared to the previous year's 54.18 billion. Losses were -46.63 billion, -43.43% less than in 2024.

Financial Statements